Metabolism - Clinical and Experimental
Volume 54, Issue 5, Supplement , Pages 33-38 , May 2005

Depression, cytokines, and glial function

  • Diane B. Miller

      Affiliations

    • Corresponding Author InformationCorresponding author. Chronic Stress and Neurotoxicology Laboratory, TMBB-HELD, CDC-NIOSH, Morgantown, WV 26505, USA. Tel.: +1 304 285 5732; fax: +1 304 285 6266.
    • ,
  • James P. O'Callaghan

References 

  1. Storr A. Churchill's black dog, Kafka's mice, and other phenomena of the human mind. New York (NY): Ballantine Books; 1990;
  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.. Washington (DC): American Psychiatric Association; 1994;
  3. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci. 2002;23:238–245
  4. Caspi A, Sugen K, Moffitt TE, et al. Influence of life stress on depression; moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386–389
  5. Kendler KS, Thornton LM, Gardner CO. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry. 2001;158:582–586
  6. McEwen BS. Glucocorticoids, depression and mood disorders: structural remodeling in the brain. Metabolism. 2005;54(Suppl.):20–23
  7. Hamet P, Tremblay J. Genetics of depression. Metabolism. 2005;
  8. Penninx BWJH, Geerlings SW, Deeg DJH, et al. Minor and major depression and the risk of death in older persons. Arch Gen Psychiatry. 1999;56:889–895
  9. Chisholm D, Sanderson K, Ayuso-Mateos JL, et al. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry. 2004;184:393–401
  10. Jackson S. Galen—on mental disorders. J Hist Behav Sci. 1969;5:365–384
  11. Paus T, Barrett J. Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression. J Psychiatry Neurosci. 2004;29:268–279
  12. Maes M, Smith RS. Fatty acids, cytokines, and major depression. Biol Psychiatry. 1998;43:313–314
  13. Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: longer-term outcome. Biol Psychiatry. 2002;51:280–287
  14. Tiemeier H, Ruud van Tuijl HR, Hofman A, et al. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am J Clin Nutr. 2003;78:40–46
  15. Smith LL. Cytokine hypothesis of overtraining: a physiological adaptation to excessive stress?. Med Sci Sports Exerc. 2000;32:317–331
  16. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:11–38
  17. Miller NE. Some psychophysiological studies of motivation and of the behavioural effects of illness. Bull Br Psychol Soc. 1964;17:1–21
  18. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157:683–694
  19. Newman EA, Volterr A. Glial control of synaptic function. Glia. 2004;47:207–208
  20. Rose CR, Blum R, Pichler B. Truncated TrkB-T1 mediates neurotrophin-evoked calcium signaling in glia cells. Nature. 2003;426:74–78
  21. Miller AH. Cytokines and sickness behavior: implications for cancer care and control. Brain Behav Immun. 2003;17:S132–S134
  22. Kelley KW, Bluthe R-M, Dantzer R, et al. Cytokine-induced sickness behavior. Brain Behav Immun. 2003;17:S112–S118
  23. Sriram K, Benkovic SA, Hebert MA, et al. Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration. J Biol Chem. 2004;279:19936–19947
  24. Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med. 2003;35:2–11
  25. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-α. Biol Psychiatry. 2004;56:819–824
  26. Capuron L, Hauser P, Hinze-Selch D, et al. Treatment of cytokine-induced depression. Brain Behav Immun. 2002;16:575–580
  27. Dantzer R, Wollman EE, Yirmiya R. Cytokines, stress, and depression. New York (NY): Plenum, Kluwer Academic; 1999;
  28. De Beaurepaire R. Questions raised by the cytokine hypothesis of depression. Brain Behav Immun. 2002;16:610–617
  29. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol. 1999;461:25–46
  30. Maes M. The depressogenic effects of cytokines: implications for the psychological and organic aetiology and treatment of depression. Int J Neuropsychopharmacol. 2002;5:375–388
  31. Smith RS. The macrophage theory of depression. Med Hypotheses. 1991;35:298–306
  32. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol. 2002;5:375–388
  33. Pollak Y, Orion E, Goshen I, et al. Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of ‘depression due to multiple sclerosis’. Brain Behav Immun. 2002;16:533–543
  34. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun. 2003;17:S119–S124
  35. Hestad KA, Tonseth S, Stoen CD, et al. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT. 2003;19:183–188
  36. Castanon N, Leonard BE, Neveu PJ, et al. Effects of antidepressants on cytokine production and actions. Brain Behav Immun. 2002;16:569–574
  37. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry. 2000;48:740–754
  38. Sapolsky RM. Is impaired neurogenesis relevant to the affective symptoms of depression?. Biol Psychiatry. 2004;56:137–139
  39. D'Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord. 2002;4:183–194
  40. Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry. 2000;48:755–765
  41. Cotter D, Mackay D, Landau S, et al. Reduced glial cell density and neuronal size in the anterior cingulated cortex in major depressive disorder. Arch Gen Psychiatry. 2001;58:545–553
  42. Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull. 2001;55:585–595
  43. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry. 2000;48:766–777
  44. Sheline YI. Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry. 2003;54:338–352
  45. Sheline Y, Wany P, Gado M, et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A. 1996;93:3908–3913
  46. Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport. 1998;9:2023–2028
  47. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516–1518
  48. Stockmeier CA, Rajkowska G. Cellular abnormalities in depression: evidence from postmortem brain tissue. Dialogues Clin Neurosci. 2004;6:185–197
  49. Vythilingam M, Vermetten E, Anderson GM, et al. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry. 2004;56:101–112
  50. Liotti M, Mayberg HS, McGinnis S, et al. Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am J Psychiatry. 2002;159(11):1830–1840
  51. Mayberg HS, Silva JA, Brannan SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002;159:728–737
  52. Frodl T, Meisenzahl E, Zetzsche T, et al. Enlargement of the amygdala in patients with a first episode of major depression. Biol Psychiatry. 2002;51:708–714
  53. Eastwood SL, Harrison PJ. Synaptic pathology in the anterior cingulated cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin. GAP-43 and the complexins. Brain Res Bull. 2001;55:569–578
  54. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45:1085–1098
  55. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A. 1998;95:13290–13295
  56. Bowley MP, Drevets WC, Ongur D, Price JL. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry. 2002;52:404–412
  57. Coyle JT, Schwarcz R. Mind glue: implications of glial cell biology for psychiatry. Arch Gen Psychiatry. 2000;57:90–93
  58. Damadzic R, Bigelow LB, Krimer LS, et al. A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis. Brain Res Bull. 2001;55:611–618
  59. Miguel-Hidalgo JJ, Baucom C, Dilley G, et al. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry. 2000;48:861–873
  60. Si X, Miguel-Hidalgo JJ, O'Dwyer G, et al. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacol. 2004;[advance online publication 7 July]
  61. Johnston-Wilson NL, Sims CD, Hofmann JP, et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry. 2000;5:142–149
  62. Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry. 2004;[advance online publication, 10 August]
  63. Hakak Y, Walker JR, Li C, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A. 2001;98:4746–4751
  64. Tkachev D, Mimmack ML, Ryan MM. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003;362:798–805
  65. Faulkner JR, Hermann JE, Woo MJ, et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci. 2004;24:2143–2155
  66. St. Pierre BA, Merrill JE, Dopp JM. Effects of cytokines on CNS cells: Glia. In:  Ransohoff RM,  Benveniste EN editor. Cytokines and the CNS. Boca Raton (Fla): CRC Press, Inc; 1996;p. 152–168
  67. Little AR, Benkovic SA, Miller DB, et al. Chemically-induced neuronal damage and gliosis: Enhanced expression of the proinflammatory chemokine, monocyte chemoattractant protein (MCP)-1, without a corresponding increase in proinflammatory cytokines. Neurosci. 2002;115:307–320

PII: S0026-0495(05)00033-8

doi: 10.1016/j.metabol.2005.01.011

Metabolism - Clinical and Experimental
Volume 54, Issue 5, Supplement , Pages 33-38 , May 2005

Article Tools